Review
doi: 10.3109/07357907.2015.1104689.
Epub 2016 Feb 11.
XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis
Affiliations
- PMID: 26864862
- DOI: 10.3109/07357907.2015.1104689
Item in Clipboard
Review
XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis
Cancer Invest.
2016.
Abstract
This meta-analysis aims to evaluate chemotherapy with XELOX (capecitabine plus oxaliplatin) versus FOLFOX (fluorouracil plus oxaliplatin) as a treatment for metastatic colorectal cancer (mCRC) in terms of efficacy and safety. Only randomized controlled trials (RCTs) comparing XELOX versus FOLFOX were included. A total of 4,363 patients from eight RCTs were available for analysis. Pooled analysis revealed that there were no statistical differences between both arms in OS, and ORR. XELOX arm had a higher incidence of thrombocytopenia, hand-foot syndrome, and diarrhea, whereas neutropenia had a higher incidence in the FOLFOX group. For mCRC, the effect of XELOX is similar to FOLFOX.
Keywords: Capecitabine; Colorectal cancer; Fluorouracil; Oxaliplatin.
Similar articles
-
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.Int J Cancer. 2011 Feb 1;128(3):682-90. doi: 10.1002/ijc.25369. Int J Cancer. 2011. PMID: 20473862 Clinical Trial.
-
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.J Clin Oncol. 2008 Apr 20;26(12):2006-12. doi: 10.1200/JCO.2007.14.9898. J Clin Oncol. 2008. PMID: 18421053 Clinical Trial.
-
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.Ann Oncol. 2008 Oct;19(10):1720-6. doi: 10.1093/annonc/mdn370. Epub 2008 Jun 10. Ann Oncol. 2008. PMID: 18550577 Clinical Trial.
-
FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.Medicine (Baltimore). 2018 Mar;97(10):e0097. doi: 10.1097/MD.0000000000010097. Medicine (Baltimore). 2018. PMID: 29517682 Free PMC article. Review.
-
Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer?Clin Colorectal Cancer. 2008 May;7(3):206-11. doi: 10.3816/CCC.2008.n.029. Clin Colorectal Cancer. 2008. PMID: 18621641 Review.
Cited by
-
Practical strategies to manage cancer patients during the COVID-19 pandemic: Saudi Oncology Pharmacy Assembly Experts recommendations.J Oncol Pharm Pract. 2020 Sep;26(6):1429-1440. doi: 10.1177/1078155220935564. Epub 2020 Jun 24. J Oncol Pharm Pract. 2020. PMID: 32580641 Free PMC article.
-
The potential effects and mechanisms of Gegen Qinlian Decoction in oxaliplatin-resistant colorectal cancer based on network pharmacology.Heliyon. 2022 Oct 30;8(11):e11305. doi: 10.1016/j.heliyon.2022.e11305. eCollection 2022 Nov. Heliyon. 2022. PMID: 36353164 Free PMC article.
-
Clinical factors related to severe enterocolitis after adjuvant CAPOX for colorectal cancer: a retrospective analysis.Ecancermedicalscience. 2020 Feb 24;14:1014. doi: 10.3332/ecancer.2020.1014. eCollection 2020. Ecancermedicalscience. 2020. PMID: 32256697 Free PMC article.
-
CTCF promotes colorectal cancer cell proliferation and chemotherapy resistance to 5-FU via the P53-Hedgehog axis.Aging (Albany NY). 2020 Jul 20;12(16):16270-16293. doi: 10.18632/aging.103648. Epub 2020 Jul 20. Aging (Albany NY). 2020. PMID: 32688344 Free PMC article.
-
Stage IV Colorectal Cancer at Initial Presentation versus Progression during and after Treatment, Differences in Management: Management Differences for Initial Presentation versus Progression of Disease after Initial Treatment.Clin Colon Rectal Surg. 2023 Apr 16;37(2):108-113. doi: 10.1055/s-0043-1761626. eCollection 2024 Mar. Clin Colon Rectal Surg. 2023. PMID: 38322603 Free PMC article. Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
